Navigation Links
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
Date:2/3/2009

Topical Delivery of ESBA105, an Anti-TNF Alpha Antibody Fragment in Patients Undergoing Cataract Surgery

ZURICH, Switzerland, Feb. 3 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of a Phase Ib/IIa study in patients undergoing cataract surgery. This study is designed to evaluate the safety, tolerability, and ocular pharmacokinetics (PK) of topically applied ESBA105 in patients, as well as assess the preventive activity on ocular inflammation resulting from the surgery. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a major mediator of inflammation. The study contains a randomized, double-blind, placebo controlled part and is being conducted as a monocentric trial in Switzerland.

The primary objectives of this study are to assess the local tolerability and safety of topical ESBA105 as well as to evaluate its intraocular levels and local biodistribution in the human eye. Secondary objectives include the assessment of the anti-inflammatory potential of prophylactic, topical ESBA105 for prevention of post-surgical inflammation following cataract surgery.

Michael A. Thiel, M.D., Ph.D., principal investigator of this study and head of the Department of Ophthalmology at the Kantonsspital in Lucerne, Switzerland, commented, "Our team has previously published the basic feasibility of applying single-chain antibody fragments to the eye. With ESBA105, the people from ESBATech have introduced for the first time a single-chain antibody fragment that carries all necessary characteristics for clinical use. I look forward to the evaluation of ESBA105 in this human PK study."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "Progress has been lacking in the development of novel treatments for inflammatory ocular conditions. We are very pleased to advance our compound into clinical Phase Ib/IIa, o
'/>"/>

SOURCE ESBATech
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
2. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
3. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
8. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... researchers have found that even before infants begin to speak, ... infants, words influence performance in a cognitive task in a ... sounds, including musical tones. The research by ... department in the Weinberg College of Arts and Sciences, will ...
... ... three drive autoloader with a compact body suitable for any office space. , ... (Vocus) March 25, 2010 -- Vinpower Digital announced today the ... autoloader duplication system. This unit offers many of the options and benefits expected ...
... ... purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a ... ... Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited ...
... ... technology can transform the way utilities can deliver power to customers," said President & ... ... have discovered that smart grid will change every aspect of their business -- from ...
... UCSF researchers have shown that delivering HIV prevention services to ... their sexual risk behaviors. The findings are available now ... Behavior " and are scheduled for publication in an upcoming ... reductions in sexual risk took place when the prevention interventions ...
... in normal-weight women, suggesting it protects against obesity , WEDNESDAY, ... a well-known marker of inflammation may help determine how much ... was not present in obese individuals, according to the research, ... March 25 issue of the New England Journal of ...
Cached Medicine News:Health News:Talk to your babies 2Health News:Vinpower Digital Introduces the 3 Drive CUBE Autoloader Series 2Health News:Aderans Research Acquires Intercytex Assets 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3Health News:UCSF study finds clinic-based HIV prevention is effective in reducing risk behaviors 2Health News:Inflammation Molecule May Determine Fat Levels 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: